OM
LENZ

Opaleye Management’s LENZ Therapeutics LENZ Stock Holding History

Opaleye Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-82,464
Closed -$1.83M – 48
2022
Q3 		$1.83M Buy
82,464
+16,750
+25% +$399K 0.76% 26
2022
Q2 		$1.26M Buy
65,714
+29,214
+80% +$651K 0.57% 36
2022
Q1 		$1.3M Buy
+36,500
New +$2.28M 0.4% 37

Other funds holding LENZ

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Opaleye Management's LENZ Position: Q4 2022 in Review

Opaleye Management sold out of LENZ Therapeutics (LENZ) in Q4 2022, closing a stake of 82,464 shares — an estimated $1.83M sold.

Opaleye Management first reported a position in LENZ in Q1 2022 and held it in 3 quarters. The position peaked at $1.83M in Q3 2022. 66 funds tracked by Wall St. Rank hold LENZ as of Q4 2022.

  • Opaleye Management reported no remaining LENZ Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Opaleye Management sold 82,464 LENZ Therapeutics shares in Q4 2022, an estimated $1.83M.
  • Opaleye Management first reported a position in LENZ Therapeutics in Q1 2022 and held it in 3 quarters.
  • Opaleye Management's LENZ Therapeutics position peaked at $1.83M in Q3 2022.
  • 66 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q4 2022.

Based on Opaleye Management's 13F filing for Q4 2022, filed 10 Feb 2023.